Public Offering

Civista Bancshares (NASDAQ: CIVB) priced an offering of 3.29 million common shares at $21.25 each, aiming to raise ~$70 million. With an underwriters’ option, proceeds could reach $80.5 million. The capital, expected to close July 14, will fund organic growth and potential acquisitions in Midwest markets. Piper Sandler leads the transaction under Civista’s existing SEC shelf registration.

VERSES AI Inc. (OTCQB: VRSSD) priced a public offering of 1,007,764 units at US$6.946 each, aiming for gross proceeds of approximately $7 million. Each unit includes one Class A subordinate voting share and one-half warrant. Full warrants are exercisable at US$8.409 per share for 36 months. Proceeds will support the company’s balance sheet, research & development initiatives, and operational needs. The offering is led by agents A.G.P. Canada Investments ULC and U.S. affiliate A.G.P./Alliance Global Partners.

Ascent Solar Technologies is offering 1,000,000 shares of common stock or pre-funded warrants, alongside warrants for another 1,000,000 shares, priced at $2.00 per share. The offering, led by H.C. Wainwright & Co., aims to raise $2 million, with an anticipated close by June 30, 2025. Proceeds will fund working capital, product development, and general expenses. The company’s focus is on high-performance flexible solar panels for various applications.

Achieve Life Sciences priced a public offering of common stock and warrants at $3.00 per share to fund its cytisinicline program, targeting nicotine dependence. The offering, expected to close around June 30, 2025, aims to raise approximately $45 million, which will be used to advance cytisinicline through the FDA approval process. Cytisinicline, with Breakthrough Therapy designation, is designed to interact with nicotine receptors, potentially aiding smoking cessation.

Julong Holding Limited (JLHL) priced its IPO at $4.00 per share, raising approximately $5.0 million through the offering of 1,250,000 Class A ordinary shares. JLHL, trading on Nasdaq as “JLHL” from June 26, 2025, provides intelligent integrated solutions for various properties in China. US Tiger Securities, Inc. acted as the sole book-runner. The offering is expected to close on June 27, 2025.

Kratos Defense & Security Solutions announced a public offering of 12,987,013 shares at $38.50, raising approximately $483.75 million. Closing on June 27, 2025, the proceeds will fund program scaling, new awards, acquisitions, and debt reduction, bolstering Kratos’ position in defense and national security. The offering is managed by Baird, RBC Capital Markets, Truist Securities, and Raymond James, supporting Kratos’ advanced technology development.

Torrid Holdings Inc. announced a public offering of 10,000,000 shares of common stock at $3.50, led by selling stockholders, with a closing expected around June 26, 2025. Underwriters have an option to purchase more shares. Concurrently, Torrid will repurchase $20.0 million of its stock from Sycamore Partners. Torrid will not receive proceeds from the offering. BofA Securities, Jefferies, and William Blair are managing the offering. Detailed information can be found in SEC filings.

Chewy, Inc. announced a major shareholder’s sale of 23.9 million shares at $41.95 with a concurrent $100 million share repurchase by the company. This move, backed by a special committee, is separate from an existing $500 million repurchase program. The transactions, expected to close by June 25, 2025, signal confidence in Chewy’s strategy within the evolving online pet market, offering an opportunity for BC Partners to realize returns.

Oklo Inc., an advanced nuclear technology firm, is launching a public offering of 6,666,667 Class A shares at $60.00 each, potentially raising $400 million. The capital will fund operations and future investments. Goldman Sachs and BofA Securities are leading the offering, expected to close June 16, 2025. Oklo aims to develop clean, reliable energy via fast fission power plants, while also focusing on radioisotope production and fuel recycling.

Insmed Incorporated announced a $750 million public offering of common stock, selling 7,812,500 shares at $96.00 each. Proceeds will fund brensocatib’s R&D, ARIKAYCE’s commercialization, and pipeline expansion. This strategic move aims to bolster financial standing and accelerate drug development across pulmonary and inflammatory conditions. The offering, led by major financial institutions, is expected to close on June 13, 2025, subject to customary conditions.